- Guide to PHARMACOLOGY
Compound class: Endogenous peptide in human, mouse or rat
Comment: Biologically active IL-10 is a homodimer. It is an anti-inflammatory cytokine.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Interleukin-10 (IL-10) is a type II cytokine and the originating member of a family of structurally related cytokines that includes IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. All family members activate JAK/STAT signalling pathways. Variety in biological activities is determined by the cells producing the cytokine, the cells responding to them, and the local immune environment exposed to them.
IL-10 is an anti-inflammatory cytokine principally produced by T-helper type 2 (Th2) cells, subsets of regulatory T cells designated Tr1, Th1, and Th17 cells . CD8+ T cells, monocytes, stimulated macrophages, subsets of dendritic cells (DCs), B cells  and granulocytes (e.g. eosinophils and mast cells ) also produce IL-10 to some extent. Some non-immune cells such as keratinocytes, epithelial cells, and tumor cells are sources of IL-10.
An immunocytokine that fuses IL-10 to an antibody to the extra-domain A of fibronectin called Dekavil (F8-IL10) is in clinical development as an anti-rheumatoid arthritis (RA) therapy . The rationale of this pharmacodelivery approach is that the monoclonal part of the agent will more effectively deliver the IL-10 to sites of disease, to increase its concentration at target tissues, but spare normal tissues. A Phase 2 safety and efficacy clinical trial of F8-IL10 in RA patients who are receiving methotrexate therapy (NCT02270632) is underway.
A pegylated version of hIL-10 (AM0010 ; INN pegilodecakin) is being investigated for immuno-onclogy potential in patients with advanced solid tumours . The most advanced trial is NCT02923921, which is a Phase 3 study that is evaluating AM0010 plus FOLFOX chemotherapy as second-line therapy for patients with metastatic pancreatic cancer. In this study the combination treatment is being directly compared to FOLFOX alone. AM0010 achieves its anti-tumour effect through activation of CD8+ T cell immunity which overcomes the cancer-induced state of intratumoural tumour-reactive T cell exhaustion .
|Immunopaedia Case Studies Links|
|In the Red|